The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Inclusion Criteria: * Histologically or cytologically confirmed head and neck cancer (HNC) or unresectable stage IIIb or IV non-small cell lung cancer (NSCLC) * At least one lesion able to be used for tumor biopsy and to be measured by FDG-PET Scan * Considered suitable for treatment of NSCLC with no prior biological or immunological therapy for disease * Or considered suitable for treatment for metastatic or recurrent HNC with no prior biological or immunological therapy for disease Exclusion Criteria: * NSCLC: Have received more than 2 previous chemotherapy regimens or have received the last chemotherapy or radiotherapy within 28 days of first dose of AZD2171 * HNC: Previous chemotherapy or radiotherapy if received 28 days of first dose of AZD2171 * Untreatable, unstable brain or meningeal metastases. * Abnormal liver and kidney blood chemistries * History of poorly controlled hypertension with resting blood pressure of \>150/100 * Recent (\< 14 days) major surgery or a surgical incision not fully healed * Diabetes patients with type I insulin dependent diabetes or poorly controlled type II * Significant hemorrhage or hemoptysis * Presence of necrotic/hemorrhagic tumor or metastases